

Sugemalimab Biosimilar - Research Grade

Product Code: ICH5278

More Information

Species Reactivity: Human

Target: PD-1

Concentration: >1mg/ml

Isotype: IgG4 - lambda

Host: CHO Cells

product name H2: Sugemalimab Biosimilar - Research Grade

Antibodies against the same target: [Anti-Mouse PD-1 \(29F.1A12\) In Vivo Antibody - Low Endotoxin \(ICH1091\)](#), [Anti-PD-1 \(RMP1-14\) \(ICH1132\)](#), [Anti-Mouse PD-1 \(RMP1-14\) Recombinant Antibody \(ICH1182\)](#), [Mouse Anti-Mouse PD-1 \(29F.1A12\) Recombinant Antibody \(ICH1211\)](#), [Anti-Mouse PD-1 \(RMP1-30\) In Vivo Antibody - Low Endotoxin \(ICH1246\)](#), [Anti-Human PD-1 \(J110\) In Vivo Antibody - Low Endotoxin \(ICH1272\)](#), [Nivolumab Biosimilar - Research Grade \(ICH4009\)](#), [Pembrolizumab Biosimilar - Research Grade \(ICH4029\)](#), [Sintilimab Biosimilar - Research Grade \(ICH5001\)](#), [Toripalimab Biosimilar - Research Grade \(ICH5002\)](#), [Camrelizumab Biosimilar - Research Grade \(ICH5003\)](#), [Tislelizumab Biosimilar - Research Grade \(ICH5004\)](#), [Penpulimab Biosimilar - Research Grade \(ICH5112\)](#), [Cemiplimab Biosimilar - Research Grade \(ICH5161\)](#), [Peresolimab Biosimilar - Research Grade \(ICH5221\)](#), [Acrixolimab Biosimilar - Research Grade \(ICH5224\)](#), [Adebrelimab Biosimilar - Research Grade \(ICH5225\)](#), [Enlonstobart Biosimilar - Research Grade \(ICH5234\)](#), [Ezabenlimab Biosimilar - Research Grade \(ICH5238\)](#), [Finotonlimab Biosimilar - Research Grade \(ICH5241\)](#), [Geptanolimab Biosimilar - Research Grade \(ICH5243\)](#), [Iparomlimab Biosimilar - Research Grade \(ICH5248\)](#), [Lipustobart Biosimilar - Research Grade \(ICH5254\)](#), [Nofazinlimab Biosimilar - Research Grade \(ICH5262\)](#), [Pimivalimab Biosimilar - Research Grade \(ICH5266\)](#), [Pradusinstobart Biosimilar - Research Grade \(ICH5268\)](#), [Pucotenlimab Biosimilar - Research Grade \(ICH5269\)](#), [Zimberelimab](#)

[Biosimilar - Research Grade \(ICH5292\)](#), [Retifanlimab Biosimilar - Research Grade \(ICH5296\)](#), [Dostarlimab Biosimilar - Research Grade \(ICH5311\)](#), [Balstilimab Biosimilar - Research Grade \(ICH5369\)](#), [Budigalimab Biosimilar - Research Grade \(ICH5417\)](#), [Cetrelimab Biosimilar - Research Grade \(ICH5434\)](#), [Gilvetmab Biosimilar - Research Grade \(ICH5572\)](#), [Lodapolimab Biosimilar - Research Grade \(ICH5651\)](#), [Pidilizumab Biosimilar - Research Grade \(ICH5773\)](#), [Prolgolimab Biosimilar - Research Grade \(ICH5791\)](#), [Rosnilimab Biosimilar - Research Grade \(ICH5837\)](#), [Rulonilimab Biosimilar - Research Grade \(ICH5840\)](#), [Sasanlimab Biosimilar - Research Grade \(ICH5848\)](#), [Serplulimab Biosimilar - Research Grade \(ICH5855\)](#), [Spartalizumab Biosimilar - Research Grade \(ICH5881\)](#), [Zeluvalimab Biosimilar - Research Grade \(ICH6006\)](#)

Sequence: <https://www.imgt.org/mAb-DB/>

Buffer: ICH3002

UniProt: Q15116

Shipping Conditions: Blue ice

background: Sugemalimab Biosimilar (Research Grade, ICH5278) is an unconjugated, non-therapeutic analog of the originator anti-PD-L1 antibody sugemalimab, produced for research use only. It is built to engage the same molecular target as the reference drug, programmed death-ligand 1 (PD-L1/CD274), and is supplied as a full-length human IgG4-lambda immunoglobulin matching the reported isotype of the originator. As a research-grade biosimilar it is intended for in-vitro and functional studies rather than any clinical or diagnostic application. Sugemalimab is a fully human anti-PD-L1 monoclonal that blocks the PD-1/PD-L1 checkpoint axis; the originator has been developed in oncology, including non-small cell lung cancer. This analog lets investigators study PD-L1 engagement, ligand-receptor blockade, and downstream immune readouts without sourcing clinical material. It is offered at low endotoxin levels suitable for sensitive cell-based assays and is available in bulk milligram-to-gram quantities as an in-vivo/assay standard. Note the supplied card labels the target as PD-1; the drug and UniProt entry correspond to PD-L1, so the material should be understood as anti-PD-L1. PD-L1 (CD274, B7-H1) is the primary ligand for the inhibitory receptor PD-1 and is the actual target of sugemalimab (UniProt Q15116). It is a type I transmembrane glycoprotein of the B7 family expressed on tumor cells, antigen-presenting cells, and many stromal and epithelial tissues, often upregulated by interferon-gamma and other inflammatory signals. Engagement of PD-L1 with PD-1 on activated T cells delivers an inhibitory signal that dampens T-cell receptor signaling, reduces

proliferation and cytokine production, and promotes T-cell exhaustion, a key mechanism of tumor immune evasion. PD-L1 also binds CD80 (B7-1). Antibodies that block PD-L1 free PD-1-bearing effector T cells from this brake, restoring cytotoxic anti-tumor responses. Because the checkpoint acts at the ligand side, anti-PD-L1 reagents are widely used to interrogate immune-suppression pathways in vitro.

Other names: Protein PD-1, hPD-1, Programmed cell death protein 1, PDCD1

Specificity: Detects human PD-1

Purification Method: This monoclonal antibody was purified using Protein A

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity: >95% by SDS-PAGE

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Delivery Time: 4 weeks